SG10201601089UA - Therapeutic Use Of A TLR Agonist And Combination Therapy - Google Patents
Therapeutic Use Of A TLR Agonist And Combination TherapyInfo
- Publication number
- SG10201601089UA SG10201601089UA SG10201601089UA SG10201601089UA SG10201601089UA SG 10201601089U A SG10201601089U A SG 10201601089UA SG 10201601089U A SG10201601089U A SG 10201601089UA SG 10201601089U A SG10201601089U A SG 10201601089UA SG 10201601089U A SG10201601089U A SG 10201601089UA
- Authority
- SG
- Singapore
- Prior art keywords
- combination therapy
- therapeutic use
- tlr agonist
- tlr
- agonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38896710P | 2010-10-01 | 2010-10-01 | |
| US38895310P | 2010-10-01 | 2010-10-01 | |
| US39044710P | 2010-10-06 | 2010-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201601089UA true SG10201601089UA (en) | 2016-03-30 |
Family
ID=45893802
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013021803A SG189071A1 (en) | 2010-10-01 | 2011-10-03 | Therapeutic use of a tlr agonist and combination therapy |
| SG10201601089UA SG10201601089UA (en) | 2010-10-01 | 2011-10-03 | Therapeutic Use Of A TLR Agonist And Combination Therapy |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013021803A SG189071A1 (en) | 2010-10-01 | 2011-10-03 | Therapeutic use of a tlr agonist and combination therapy |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20120219615A1 (de) |
| EP (2) | EP3195868A3 (de) |
| JP (2) | JP5951615B2 (de) |
| KR (1) | KR101866893B1 (de) |
| CN (2) | CN103458902B (de) |
| AU (2) | AU2011308504B2 (de) |
| BR (1) | BR112013007681A2 (de) |
| CA (1) | CA2812790A1 (de) |
| ES (1) | ES2616449T3 (de) |
| IL (1) | IL225463A (de) |
| MX (1) | MX340290B (de) |
| NZ (1) | NZ608673A (de) |
| RU (2) | RU2016141322A (de) |
| SG (2) | SG189071A1 (de) |
| WO (1) | WO2012045090A2 (de) |
Families Citing this family (145)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140096092A (ko) | 2011-11-17 | 2014-08-04 | 바이엘 메디컬 케어 인크. | 의료 진단 절차들에 관한 정보를 수집하고 보고하고 관리하는 방법들 및 기법들 |
| WO2015023958A1 (en) * | 2013-08-15 | 2015-02-19 | The University Of Kansas | Toll-like receptor agonists |
| JP2017503803A (ja) | 2014-01-10 | 2017-02-02 | シャンハイ バーディー バイオテック インコーポレイテッド | Ｅｇｆｒ発現腫瘍を処置するための化合物及び組成物 |
| ES2804101T3 (es) | 2014-04-22 | 2021-02-03 | Hoffmann La Roche | Compuestos de 4-amino-imidazoquinolina |
| AU2015301054B2 (en) | 2014-08-08 | 2020-05-14 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
| EP3722297A1 (de) | 2015-03-04 | 2020-10-14 | Gilead Sciences, Inc. | Toll-like-rezeptor-modulator-verbindungen |
| HUE042563T2 (hu) * | 2015-03-06 | 2019-07-29 | Hoffmann La Roche | Benzazepin-dikarboxamid vegyületek |
| CA2995004A1 (en) | 2015-08-26 | 2017-03-02 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
| EP3349757A1 (de) | 2015-09-15 | 2018-07-25 | Gilead Sciences, Inc. | Modulatoren von toll-like-rezeptoren zur behandlung von hiv |
| CN108367011A (zh) | 2015-11-02 | 2018-08-03 | 文蒂雷克斯药品公司 | 使用tlr8激动剂治疗癌症 |
| LT3390441T (lt) | 2015-12-15 | 2021-11-10 | Gilead Sciences, Inc. | Žmogaus imunodeficito virusą neutralizuojantys antikūnai |
| CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| EP3464245B1 (de) | 2016-05-23 | 2020-10-14 | H. Hoffnabb-La Roche Ag | Benzazepindicarboxamidverbindungen mit tertiärer amidfunktion |
| WO2017202703A1 (en) | 2016-05-23 | 2017-11-30 | F. Hoffmann-La Roche Ag | Benzazepine dicarboxamide compounds with secondary amide function |
| CN118178444A (zh) | 2016-05-27 | 2024-06-14 | 吉利德科学公司 | 使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法 |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| EP3468963B1 (de) | 2016-06-12 | 2021-10-27 | F. Hoffmann-La Roche AG | Dihydropyrimidinyl-benzazepincarboxamide verbindungen |
| WO2018004747A1 (en) * | 2016-06-27 | 2018-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Therapeutic antitumor combination of a tlr4 ligand with other treatments |
| WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| CR20190181A (es) | 2016-10-14 | 2019-08-21 | Prec Biosciences Inc | Meganucleasas diseñadas específicamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b. |
| US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
| US20180206726A1 (en) | 2016-12-07 | 2018-07-26 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018112223A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a tlr modulator |
| TWI820984B (zh) | 2017-01-31 | 2023-11-01 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| WO2018232725A1 (en) | 2017-06-23 | 2018-12-27 | Birdie Biopharmaceuticals, Inc. | PHARMACEUTICAL COMPOSITIONS |
| WO2019010243A1 (en) | 2017-07-07 | 2019-01-10 | Bayer Healthcare Llc | APPARATUS, METHOD AND COMPUTER PROGRAM PRODUCT FOR EXCHANGING DATA EXCHANGE BETWEEN INJECTION SYSTEMS |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| TW202024061A (zh) | 2017-08-17 | 2020-07-01 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| KR20200043439A (ko) | 2017-08-22 | 2020-04-27 | 길리애드 사이언시즈, 인코포레이티드 | 치료 헤테로시클릭 화합물 |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| KR20200100113A (ko) | 2017-12-15 | 2020-08-25 | 실버백 테라퓨틱스, 인크. | 간염 치료용 항체 구조물-약물 접합체 |
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| JP7098748B2 (ja) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド |
| CN108096576B (zh) * | 2017-12-28 | 2021-09-03 | 中国医学科学院医学实验动物研究所 | Tlr8激活剂在制备结核疫苗佐剂中的用途及其制备的结核疫苗 |
| PL3752501T3 (pl) | 2018-02-13 | 2023-08-21 | Gilead Sciences, Inc. | Inhibitory pd-1/pd-l1 |
| EP3752495B1 (de) | 2018-02-15 | 2023-07-19 | Gilead Sciences, Inc. | Pyridinderivate und ihre verwendung zur behandlung von hiv-infektionen |
| AR114631A1 (es) | 2018-02-16 | 2020-09-30 | Gilead Sciences Inc | Métodos e intermedios para preparar compuestos de piridina |
| WO2019165374A1 (en) | 2018-02-26 | 2019-08-29 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| EP3781556A1 (de) | 2018-04-19 | 2021-02-24 | Gilead Sciences, Inc. | Pd-1/pd-l1-inhibitoren |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| WO2020010107A1 (en) | 2018-07-03 | 2020-01-09 | Gilead Sciences, Inc. | Antibodies that target hiv gp120 and methods of use |
| WO2020010200A1 (en) | 2018-07-06 | 2020-01-09 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| JP7199502B2 (ja) | 2018-07-06 | 2023-01-05 | ギリアード サイエンシーズ， インコーポレイテッド | 治療用複素環式化合物 |
| PT3820572T (pt) | 2018-07-13 | 2023-11-10 | Gilead Sciences Inc | Inibidores pd-1/pd-l1 |
| KR20210033492A (ko) | 2018-07-16 | 2021-03-26 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료를 위한 캡시드 억제제 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| JP2022500414A (ja) | 2018-09-12 | 2022-01-04 | シルバーバック セラピューティックス インコーポレイテッド | 免疫刺激性コンジュゲートにより疾患を処置する方法および組成物 |
| WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| CN113227089A (zh) | 2018-10-31 | 2021-08-06 | 吉利德科学公司 | 作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物 |
| CA3116347A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| CA3128386A1 (en) | 2019-02-04 | 2020-08-13 | Codiak Biosciences, Inc. | Membrane protein scaffolds for exosome engineering |
| WO2020176510A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
| WO2020176505A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
| CN113574063A (zh) | 2019-03-07 | 2021-10-29 | 捷克共和国有机化学与生物化学研究所 | 3’3’-环二核苷酸及其前药 |
| EP3934757B1 (de) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-zyklische dinukleotide und prodrugs davon |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| EP3937984A1 (de) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Gegen her2 gerichtete immunkonjugate |
| US20220175762A1 (en) * | 2019-03-15 | 2022-06-09 | Birdie Biopharmaceuticals, Inc. | Immune modulatory compositions and methods for treating cancers |
| US20220387906A1 (en) | 2019-03-21 | 2022-12-08 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
| SG11202109702QA (en) | 2019-03-21 | 2021-10-28 | Codiak Biosciences Inc | Extracellular vesicles for vaccine delivery |
| MX2021011242A (es) | 2019-03-21 | 2022-01-19 | Codiak Biosciences Inc | Conjugados de vesícula extracelular y usos de estos. |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202231277A (zh) | 2019-05-21 | 2022-08-16 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
| EP3972695A1 (de) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituierte exo-methylen-oxindole als hpk1/map4k1-inhibitoren |
| WO2020255038A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| EP3986474A1 (de) | 2019-06-19 | 2022-04-27 | Silverback Therapeutics, Inc. | Anti-mesothelin-antikörper und immunkonjugate davon |
| CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
| US20230181758A1 (en) | 2019-07-03 | 2023-06-15 | Codiak Biosciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
| EP3994158A1 (de) | 2019-07-03 | 2022-05-11 | Codiak BioSciences, Inc. | Auf t-zellen abzielende extrazelluläre vesikel und verwendungen davon |
| US11795210B2 (en) | 2019-07-16 | 2023-10-24 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| KR20220058555A (ko) | 2019-08-15 | 2022-05-09 | 실버백 테라퓨틱스, 인크. | 벤즈아제핀 접합체의 제형 및 이의 용도 |
| EP4017476A1 (de) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmazeutische formulierungen von tenofoviralafenamid (taf) |
| JP2022549328A (ja) | 2019-09-25 | 2022-11-24 | コディアック バイオサイエンシーズ， インコーポレイテッド | 細胞外小胞組成物 |
| CN117843811A (zh) | 2019-09-30 | 2024-04-09 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| CN118178645A (zh) | 2019-10-18 | 2024-06-14 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| WO2021087064A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| KR20220106165A (ko) | 2019-11-26 | 2022-07-28 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 예방을 위한 캡시드 억제제 |
| CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
| JP2023509881A (ja) | 2019-12-24 | 2023-03-10 | カルナバイオサイエンス株式会社 | ジアシルグリセロールキナーゼ調節化合物 |
| EP4103285A2 (de) | 2020-02-14 | 2022-12-21 | Jounce Therapeutics, Inc. | Antikörper und fusionsproteine, die an ccr8 binden, und deren verwendungen |
| WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| WO2021184017A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicles for treating neurological disorders |
| JP2023518414A (ja) | 2020-03-20 | 2023-05-01 | コディアック バイオサイエンシーズ， インコーポレイテッド | 治療のための細胞外小胞 |
| JP2023518433A (ja) | 2020-03-20 | 2023-05-01 | ギリアード サイエンシーズ， インコーポレイテッド | ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法 |
| KR20230006891A (ko) | 2020-05-01 | 2023-01-11 | 길리애드 사이언시즈, 인코포레이티드 | Cd73를 억제하는 2,4-다이옥소피리미딘 화합물 |
| EP4153181A1 (de) | 2020-05-21 | 2023-03-29 | Gilead Sciences, Inc. | Pharmazeutische zusammensetzungen mit bictegravir |
| WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
| WO2021248133A1 (en) | 2020-06-05 | 2021-12-09 | Codiak Biosciences, Inc. | Anti-transferrin extracellular vesicles |
| JP2023533915A (ja) | 2020-06-25 | 2023-08-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖの治療のためのカプシド阻害剤 |
| CN116209678A (zh) | 2020-07-01 | 2023-06-02 | 安尔士制药公司 | 抗asgr1抗体缀合物及其用途 |
| AU2021300632A1 (en) | 2020-07-02 | 2023-02-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of achieving HIV viral remission using long-acting antiretroviral agents |
| CA3186054A1 (en) | 2020-08-07 | 2022-02-10 | Daniel H. BYUN | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| WO2022066898A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Methods of producing extracellular vesicles |
| WO2022066883A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Extracellular vesicles comprising kras antigens and uses thereof |
| WO2022066928A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| CN116437958A (zh) | 2020-11-11 | 2023-07-14 | 吉利德科学公司 | 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法 |
| AU2022253902A1 (en) | 2021-04-10 | 2023-11-02 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| CA3216459A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
| TW202310852A (zh) | 2021-05-13 | 2023-03-16 | 美商基利科學股份有限公司 | ＴＬＲ８調節化合物及抗ＨＢＶ ｓｉＲＮＡ療法之組合 |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CR20230585A (es) | 2021-06-23 | 2024-02-19 | Gilead Sciences Inc | Compuestos Moduladores de Diacilglicerol Quinasa. |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| AU2022376954A1 (en) | 2021-10-29 | 2024-05-02 | Gilead Sciences, Inc. | Cd73 compounds |
| US20230203071A1 (en) | 2021-12-03 | 2023-06-29 | Zhimin Du | Therapeutic compounds for hiv virus infection |
| CA3235937A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| TW202342447A (zh) | 2021-12-03 | 2023-11-01 | 美商基利科學股份有限公司 | 用於ｈｉｖ病毒感染之治療性化合物 |
| US20230220106A1 (en) | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| US20230203202A1 (en) | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ｉｋａｒｏｓ鋅指家族降解劑及其用途 |
| WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| TW202400172A (zh) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2024006982A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| WO2024044477A1 (en) | 2022-08-26 | 2024-02-29 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
| US4665077A (en) | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
| EP1603936B1 (de) * | 2003-02-28 | 2012-04-11 | Agenus Inc. | Verwendung von lektinen zur förderung der oligomerisierung von glycoproteinen und antigenen molekülen |
| AU2006216822A1 (en) * | 2005-02-22 | 2006-08-31 | Daniel Rachmilewitz | Methods of treating gastrointestinal inflammation |
| EP1874342B1 (de) * | 2005-04-26 | 2018-06-06 | Eisai R&D Management Co., Ltd. | Zusammensetzungen und verfahren für die krebsimmuntherapie |
| TWI404537B (zh) * | 2005-08-19 | 2013-08-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯 |
| CA2658584A1 (en) * | 2006-07-27 | 2008-01-31 | Ottawa Health Research Institute | Staged immune-response modulation in oncolytic therapy |
| TWI433546B (zh) * | 2008-07-03 | 2014-04-01 | Chi Lin Technology Co Ltd | 影像解析度調整裝置、顯示裝置以及影像解析度調整方法 |
| ES2438496T3 (es) | 2008-08-01 | 2014-01-17 | Ventirx Pharmaceuticals, Inc. | Formulaciones de agonistas de receptores de tipo toll y su uso |
-
2011
- 2011-10-03 SG SG2013021803A patent/SG189071A1/en unknown
- 2011-10-03 AU AU2011308504A patent/AU2011308504B2/en active Active
- 2011-10-03 EP EP16199830.7A patent/EP3195868A3/de not_active Withdrawn
- 2011-10-03 KR KR1020137011293A patent/KR101866893B1/ko active IP Right Grant
- 2011-10-03 JP JP2013531959A patent/JP5951615B2/ja not_active Expired - Fee Related
- 2011-10-03 US US13/252,147 patent/US20120219615A1/en not_active Abandoned
- 2011-10-03 CA CA2812790A patent/CA2812790A1/en not_active Abandoned
- 2011-10-03 WO PCT/US2011/054654 patent/WO2012045090A2/en active Application Filing
- 2011-10-03 NZ NZ60867311A patent/NZ608673A/en unknown
- 2011-10-03 MX MX2013003534A patent/MX340290B/es active IP Right Grant
- 2011-10-03 BR BR112013007681-0A patent/BR112013007681A2/pt not_active Application Discontinuation
- 2011-10-03 CN CN201180058051.4A patent/CN103458902B/zh active Active
- 2011-10-03 CN CN201710953736.4A patent/CN107970451A/zh active Pending
- 2011-10-03 ES ES11830073.0T patent/ES2616449T3/es active Active
- 2011-10-03 RU RU2016141322A patent/RU2016141322A/ru not_active Application Discontinuation
- 2011-10-03 RU RU2013120311/15A patent/RU2603467C2/ru active
- 2011-10-03 SG SG10201601089UA patent/SG10201601089UA/en unknown
- 2011-10-03 EP EP11830073.0A patent/EP2621500B1/de active Active
-
2013
- 2013-03-24 IL IL225463A patent/IL225463A/en active IP Right Grant
-
2016
- 2016-05-16 AU AU2016203176A patent/AU2016203176A1/en not_active Abandoned
- 2016-06-08 JP JP2016114568A patent/JP2016196482A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP5951615B2 (ja) | 2016-07-13 |
| RU2016141322A (ru) | 2018-12-14 |
| US20120219615A1 (en) | 2012-08-30 |
| WO2012045090A3 (en) | 2012-07-19 |
| AU2011308504B2 (en) | 2016-06-02 |
| EP3195868A2 (de) | 2017-07-26 |
| CA2812790A1 (en) | 2012-04-05 |
| RU2013120311A (ru) | 2014-11-20 |
| IL225463A (en) | 2017-08-31 |
| AU2011308504A1 (en) | 2013-04-18 |
| CN103458902A (zh) | 2013-12-18 |
| EP2621500A4 (de) | 2014-03-05 |
| AU2016203176A1 (en) | 2016-06-09 |
| KR20130132788A (ko) | 2013-12-05 |
| EP2621500A2 (de) | 2013-08-07 |
| SG189071A1 (en) | 2013-05-31 |
| CN107970451A (zh) | 2018-05-01 |
| BR112013007681A2 (pt) | 2019-05-14 |
| NZ608673A (en) | 2015-04-24 |
| ES2616449T3 (es) | 2017-06-13 |
| JP2016196482A (ja) | 2016-11-24 |
| MX340290B (es) | 2016-07-04 |
| EP2621500B1 (de) | 2016-11-23 |
| RU2603467C2 (ru) | 2016-11-27 |
| KR101866893B1 (ko) | 2018-06-14 |
| CN103458902B (zh) | 2017-11-07 |
| WO2012045090A2 (en) | 2012-04-05 |
| EP3195868A3 (de) | 2017-08-02 |
| JP2013538860A (ja) | 2013-10-17 |
| MX2013003534A (es) | 2013-10-03 |
| IL225463A0 (en) | 2013-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201601089UA (en) | Therapeutic Use Of A TLR Agonist And Combination Therapy | |
| IL276643A (en) | Methods to increase the transfer of drugs and the effectiveness of therapeutic agents | |
| IL272501A (en) | Oral administration forms of bendamustine and their medical use | |
| HK1173654A1 (zh) | 治療化合物及相關的使用方法 | |
| PT2600812T (pt) | Aparelho para tratar um olho | |
| EP2542086A4 (de) | Verbindungen und ihre therapeutische verwendung | |
| GB2479358B (en) | Therapeutic hand exercise device | |
| AP2013007178A0 (en) | BCMA-based stratification and therapy for multiplemyeloma patients | |
| EP2745874A4 (de) | Hilfsvorrichtung zur evaluierung einer hautdosis und therapeutische planungsvorrichtung | |
| HK1201454A1 (en) | Therapeutic agents and uses thereof | |
| GB201004020D0 (en) | New therapeutic use | |
| IL207586A0 (en) | A fibrin based therapeutic preparation and use thereof | |
| ZA201201287B (en) | Therapeutic aryl-amido-aryl compounds and their use | |
| GB201011411D0 (en) | Therapeutic compounds and their use | |
| ZA201301458B (en) | Therapeutic agent for pain | |
| PL393091A1 (pl) | Łóżko rehabilitacyjno-lecznicze | |
| IL203679A (en) | Therapeutic massager patch | |
| TWM402101U (en) | Structure of body-scraping therapeutic treatment device | |
| GB201014917D0 (en) | Therapeutic treatments | |
| GB201014918D0 (en) | Therapeutic treatments | |
| TWM401446U (en) | Skin therapy device structure | |
| ZA201403477B (en) | Apricitabine and pi combination therapy | |
| TWM400853U (en) | Massaging device of massaging chair | |
| GB201013698D0 (en) | Fixation devices and methods of use thereof | |
| GB201019938D0 (en) | Determination of therapeutic agents |